albuterol has been researched along with Hyperventilation in 24 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Hyperventilation: A pulmonary ventilation rate faster than is metabolically necessary for the exchange of gases. It is the result of an increased frequency of breathing, an increased tidal volume, or a combination of both. It causes an excess intake of oxygen and the blowing off of carbon dioxide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms), and a placebo were compared in a double-blind study in 12 adult subjects with asthma who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days." | 9.07 | Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992) |
| "The duration of effect of inhaled formoterol (24 micrograms) was compared with that of a placebo and that of inhaled albuterol (200 micrograms) in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days." | 9.06 | Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; Gontovnick, L; Malo, JL; Trudeau, C, 1990) |
| " The present study was undertaken to investigate the effect of salbutamol (SB), a highly selective beta 2 agonist, and hyperventilation (HV)-induced alkalosis on the change in serum K+ after succinylcholine (SCh) administration in dogs." | 7.67 | Effects of salbutamol and hyperventilation on the rise in serum potassium after succinylcholine administration. ( Hirasawa, H; Inaba, H; Mizuguchi, T; Ohwada, T; Sato, J, 1987) |
| "The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms), and a placebo were compared in a double-blind study in 12 adult subjects with asthma who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days." | 5.07 | Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992) |
| "The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms) and placebo was compared in a double-blind study carried out in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air on 4 study days." | 5.07 | [Duration of bronchial protective effect of salmeterol in asthma induced by hyperventilation with dry cold air]. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992) |
| "The duration of effect of inhaled formoterol (24 micrograms) was compared with that of a placebo and that of inhaled albuterol (200 micrograms) in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days." | 5.06 | Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; Gontovnick, L; Malo, JL; Trudeau, C, 1990) |
| "We present a 19-month-old boy with a history of asthma who presented to the pediatric emergency department with noisy breathing and tachypnea partially responsive to albuterol." | 3.76 | A 19-month-old boy with recurrent respiratory distress. ( Cross, KP; Herr, SM; Randell, KA, 2010) |
| " The present study was undertaken to investigate the effect of salbutamol (SB), a highly selective beta 2 agonist, and hyperventilation (HV)-induced alkalosis on the change in serum K+ after succinylcholine (SCh) administration in dogs." | 3.67 | Effects of salbutamol and hyperventilation on the rise in serum potassium after succinylcholine administration. ( Hirasawa, H; Inaba, H; Mizuguchi, T; Ohwada, T; Sato, J, 1987) |
| " The Raw and CDyn changes were prevented and reversed with the bronchodilators salbutamol and aminophylline indicating that reversible bronchospasms are induced in guinea pigs following a period of hyperventilation." | 3.67 | Hyperventilation-induced bronchoconstriction in guinea pigs. ( Chapman, RW; Danko, G, 1985) |
| "In this study, we let patients with COPD hyperventilate to evoke hyperinflation, and evaluated the effects of tiotropium alone or in combination with salmeterol on hyperventilation-evoked hyperinflation." | 2.73 | Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD. ( Eguchi, Y; Fujimoto, S; Hirata, K; Kamoi, H; Kanazawa, H; Kudoh, S; Tateishi, Y; Umeda, N; Yoshikawa, T, 2007) |
| "To study the dose-response relationship of salmeterol for protection against a naturally occurring stimulus, isocapnic hyperventilation tests of cold air were done in 16 asthmatic patients." | 2.67 | Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. ( Jörres, R; Lüthke, M; Magnussen, H; Nowak, D; Rabe, KF; Wiessmann, J, 1992) |
| " Although, the response to bronchoconstriction in dogs and rats was different from humans, the two species presented ventilatory changes that highlight the potential adverse effect of test articles." | 1.35 | Respiratory safety pharmacology: positive control drug responses in Sprague-Dawley rats, Beagle dogs and cynomolgus monkeys. ( Authier, S; Gauvin, D; Legaspi, M; Troncy, E, 2009) |
| "In patients with moderate-to-severe COPD, tiotropium did not reduce MPH-induced DH and reduction in IC, compared to baseline." | 1.34 | Tiotropium and simplified detection of dynamic hyperinflation. ( Chapman, KR; Gelb, AF; Gutierrez, CA; McClean, PA; Rodrigues, MT; Shinar, CM; Taylor, CF; Zamel, N, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (41.67) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, S | 1 |
| MacInnis, MJ | 1 |
| Sporer, BC | 1 |
| Rupert, JL | 1 |
| Koehle, MS | 1 |
| Perez, T | 1 |
| Chanez, P | 1 |
| Dusser, D | 1 |
| Devillier, P | 1 |
| Authier, S | 1 |
| Legaspi, M | 1 |
| Gauvin, D | 1 |
| Troncy, E | 1 |
| Cross, KP | 1 |
| Randell, KA | 1 |
| Herr, SM | 1 |
| Wiwanitkit, V | 1 |
| Aguilaniu, B | 1 |
| Gelb, AF | 1 |
| Taylor, CF | 1 |
| McClean, PA | 1 |
| Shinar, CM | 1 |
| Rodrigues, MT | 1 |
| Gutierrez, CA | 1 |
| Chapman, KR | 1 |
| Zamel, N | 1 |
| Eguchi, Y | 1 |
| Tateishi, Y | 1 |
| Umeda, N | 1 |
| Yoshikawa, T | 1 |
| Kamoi, H | 1 |
| Kanazawa, H | 1 |
| Kudoh, S | 1 |
| Hirata, K | 1 |
| Fujimoto, S | 1 |
| Nicholas, TE | 1 |
| Barr, HA | 1 |
| Omori, C | 1 |
| Schofield, BH | 1 |
| Mitzner, W | 1 |
| Freed, AN | 1 |
| Anderson, SD | 2 |
| Silverman, M | 1 |
| König, P | 1 |
| Godfrey, S | 1 |
| Malo, JL | 4 |
| Ghezzo, H | 4 |
| Trudeau, C | 4 |
| L'Archevêque, J | 2 |
| Cartier, A | 4 |
| Nowak, D | 1 |
| Jörres, R | 2 |
| Rabe, KF | 1 |
| Lüthke, M | 1 |
| Wiessmann, J | 1 |
| Magnussen, H | 2 |
| Gontovnick, L | 1 |
| Wiebicke, W | 1 |
| Morris, J | 1 |
| Dente, FL | 1 |
| Del Bono, L | 1 |
| Del Bono, N | 1 |
| Jamison, JP | 1 |
| Glover, PJ | 1 |
| Wallace, WF | 1 |
| Smith, CM | 1 |
| Seale, JP | 1 |
| Mussell, MJ | 1 |
| Hartley, JP | 1 |
| Inaba, H | 1 |
| Ohwada, T | 1 |
| Sato, J | 1 |
| Mizuguchi, T | 1 |
| Hirasawa, H | 1 |
| Picado, C | 1 |
| Chapman, RW | 1 |
| Danko, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Prevalence and the Reversibility of the Lung Hyperinflation in Uncontrolled Persistent Asthmatic Patients With Dyspnea[NCT01573364] | 450 participants (Actual) | Observational | 2011-02-28 | Completed | |||
| Effectiveness of Tiotropium to Maintain Inspiratory Capacity Against Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in COPD Patients With Lung CT Scored Emphysema[NCT00570544] | 29 participants (Actual) | Observational | 2004-08-31 | Completed | |||
| Simplified Detection of Dynamic Hyperinflation Using Metronome Paced Hyperventilation and the Effect of Tiotropium in Patients With COPD[NCT00569270] | Phase 4 | 30 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Lung function studies (mean +/- SD) peak Peak FRC/TLC after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity/total lung capacity - percentage (NCT00569270)
Timeframe: 30 days
| Intervention | percentage of FRC/TLC (Mean) |
|---|---|
| Placebo | 0.65 |
| Tiotropium | 0.66 |
Lung function studies (mean +/- SD) of peak forced vital capaciy (L) after 30 days (+2h) of tiotropium versus placebo in 29 moderate COPD patients. Forced vital capacity - liters (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 3.17 |
| Tiotropium 18 µg Capsule, Bronchodilator | 3.27 |
Lung function studies (mean +/- SD) - Peak inspiratory capacity after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Inspiratory capacity- liters (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 2.12 |
| Tiotropium | 2.24 |
Net change in lung function studies (mean +/- SE) from baseline to trough (-1h) and peak (+2h) after 30 days of tiotropium versus placebo in 29 moderate COPD patients. Total lung capacity - liters (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 5.91 |
| Tiotropium | 5.82 |
Lung function studies Trough FEV1(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Forced expiratory volume in 1s (liters) (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 1.68 |
| Tiotropium | 1.71 |
Lung function studies Trough FRC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity(liters) (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 3.84 |
| Tiotropium | 3.66 |
Lung function studies Trough FRC/TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough Functional residual capacity/total lung capacity - percentage (NCT00569270)
Timeframe: 30 days
| Intervention | percentage of FRC/TLC (Mean) |
|---|---|
| Placebo | 0.64 |
| Tiotropium | 0.62 |
Lung function studies Trough FVC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 3.12 |
| Tiotropium | 3.15 |
Lung function studies (Trough IC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough inspiratory capacity- liters (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 2.17 |
| Tiotropium | 2.11 |
Lung function studies Trough TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 5.99 |
| Tiotropium | 5.86 |
Lung function studies (mean +/- SD): peak FEV1 (+2h) after 30 days of placebo or tiotropium in 29 moderate COPD patients. FEV1 = Forced expiratory volume in one second (NCT00569270)
Timeframe: 30 days
| Intervention | liters (Mean) |
|---|---|
| Placebo | 1.74 |
| Tiotropium | 1.82 |
Lung function studies (mean +/- SD): peak FRC after 30 days (+2h) of placebo or tiotropium in 29 moderate COPD patients. (NCT00569270)
Timeframe: 30 days
| Intervention | Liters (Mean) |
|---|---|
| Placebo | 3.80 |
| Tiotropium | 3.72 |
Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to FEV 1; correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema; measures include increase in FEV1 from baseline to peak tiotropium (NCT00569270)
Timeframe: baseline to 30 days
| Intervention | percentage of lung tissue (Mean) |
|---|---|
| Lung CT Scored Emphysema and FEV1 | 13.68 |
Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to ratio functional residual capacity divided by total lung capacity. Specifically, correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema (NCT00569270)
Timeframe: baseline to trough tiotropium
| Intervention | percentage of lung tissue (Mean) |
|---|---|
| Lung CT Scored Emphysema and FRC/TLC | 13.68 |
Correlation between change in inspiratory capacity (L) post metronome paced hyperventilation induced dynamic hyperinflation and extent of lung ct scored emphysema (NCT00569270)
Timeframe: baseline to 30 days
| Intervention | percentage of lung tissue (Mean) |
|---|---|
| Lung CT Scored Emphysema and IC | 13.68 |
IC measurement before and after metronome paced hyperventilation-induced dynamic hyperinflation at baseline and in tiotropium and placebo groups. Measure ratio of functional residual capacity divided by total lung capacity at baseline and after 30 days of tiotropium versus placebo (NCT00569270)
Timeframe: baseline and 30 days (+2h) post dose
| Intervention | liters (Mean) | ||
|---|---|---|---|
| Baseline IC (inspiratory capacity) | Placebo IC | Tiotropium IC | |
| After DH (Dynamic Hyperinflation | 1.76 | 1.80 | 1.80 |
| Before DH (Dynamic Hyperinflation) | 2.09 | 2.17 | 2.24 |
Total lung capacity before and after metronome paced hyperventilation induced dynamic hyperinflation in tiotropium cohort versus placebo. Difference between TLC measured at one hour before intervention & 2 hrs. after after 30 days of treatment with either placebo or tiotropium (NCT00569270)
Timeframe: one hour before intervention & 2 hrs. after after 30 days
| Intervention | liters (Mean) | |
|---|---|---|
| Before DH (dynamic hyperinflation) | After DH | |
| 2h Post Placebo TLC(L) | 5.96 | 5.84 |
| TLC (L) 2h Post Tiotropium | 5.84 | 5.78 |
10 trials available for albuterol and Hyperventilation
| Article | Year |
|---|---|
Inhaled salbutamol does not affect athletic performance in asthmatic and non-asthmatic cyclists.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Athletic Performance; Bicycling; Bronchodilato | 2015 |
Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
Topics: Aged; Albuterol; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2007 |
Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Cold Temperatur | 1992 |
[Duration of bronchial protective effect of salmeterol in asthma induced by hyperventilation with dry cold air].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction | 1992 |
Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchodilator Agents; D | 1992 |
Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchoconstri | 1990 |
Comparison of the effects of inhaled corticosteroids on the airway response to histamine, methacholine, hyperventilation, and sulfur dioxide in subjects with asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Airway Resistance; Albuterol; Asthma; Beclometh | 1990 |
Duration of action of inhaled terbutaline at two different doses and of albuterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in asthmatic subjects.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Child; Cold Temperature; Female | 1989 |
Cold-air isocapnic hyperventilation test in the study of the effects and duration of action of Duovent. Comparison with fenoterol, salbutamol, disodium cromoglycate and placebo.
Topics: Adolescent; Adult; Air; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Bronch | 1986 |
Comparison of the effects of inhaled ipratropium bromide and salbutamol on the bronchoconstrictor response to hypocapnic hyperventilation in normal subjects.
Topics: Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol; Atropine Derivatives; C | 1987 |
14 other studies available for albuterol and Hyperventilation
| Article | Year |
|---|---|
Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea.
Topics: Adult; Aged; Albuterol; Asthma; Disease Progression; Dyspnea; Female; Forced Expiratory Volume; Huma | 2016 |
Respiratory safety pharmacology: positive control drug responses in Sprague-Dawley rats, Beagle dogs and cynomolgus monkeys.
Topics: Albuterol; Animals; Bronchoconstrictor Agents; Bronchodilator Agents; Dogs; Drug Evaluation, Preclin | 2009 |
A 19-month-old boy with recurrent respiratory distress.
Topics: Acid-Base Equilibrium; Albuterol; Alkalosis, Respiratory; Aspirin; Asthma; Bicarbonates; Bites, Huma | 2010 |
Acute exacerbation of asthma complicated by hyperventilation in emergency department.
Topics: Adult; Albuterol; Asthma; Emergency Service, Hospital; Female; Forced Expiratory Volume; Heart Rate; | 2010 |
[Efficacy of bronchodilators: searching for objective criteria].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Bronchodilator Agents; Dyspnea; Exe | 2003 |
Tiotropium and simplified detection of dynamic hyperinflation.
Topics: Aged; Albuterol; Bronchodilator Agents; Female; Forced Expiratory Volume; Functional Residual Capaci | 2007 |
Tiotropium and simplified detection of dynamic hyperinflation.
Topics: Aged; Albuterol; Bronchodilator Agents; Female; Forced Expiratory Volume; Functional Residual Capaci | 2007 |
Tiotropium and simplified detection of dynamic hyperinflation.
Topics: Aged; Albuterol; Bronchodilator Agents; Female; Forced Expiratory Volume; Functional Residual Capaci | 2007 |
Tiotropium and simplified detection of dynamic hyperinflation.
Topics: Aged; Albuterol; Bronchodilator Agents; Female; Forced Expiratory Volume; Functional Residual Capaci | 2007 |
Control of release of surfactant phospholipids in the isolated perfused rat lung.
Topics: Albuterol; Animals; Atropine; Bucladesine; Cyproheptadine; Dibutyryl Cyclic GMP; Hyperventilation; I | 1981 |
A beta 2-adrenergic agonist inhibits dry air-induced injury in canine peripheral airways.
Topics: Air; Airway Resistance; Albuterol; Animals; Bronchi; Bronchial Arteries; Bronchoconstriction; Capill | 1995 |
Exercise-induced asthma.
Topics: Acidosis, Respiratory; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Air | 1975 |
The duration of action of the combination of fenoterol hydrobromide and ipratropium bromide in protecting against asthma provoked by hyperpnea.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Drug Therapy | 1988 |
Trachea-noise biofeedback in asthma: a comparison of the effect of trachea-noise biofeedback, a bronchodilator, and no treatment on the rate of recovery from exercise- and eucapnic hyperventilation-induced asthma.
Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Biofeedback, Psychology; Bronchial Spasm; Double | 1988 |
Effects of salbutamol and hyperventilation on the rise in serum potassium after succinylcholine administration.
Topics: Albuterol; Anesthesia; Animals; Blood Pressure; Cardiac Output; Dogs; Hyperventilation; Insulin; Pot | 1987 |
Postcoital severe exacerbation of asthma requiring mechanical ventilation.
Topics: Acute Disease; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Coitus; Emotions; Female; Humans; | 1987 |
Hyperventilation-induced bronchoconstriction in guinea pigs.
Topics: Airway Resistance; Albuterol; Aminophylline; Animals; Atropine; Blood Gas Analysis; Bronchial Spasm; | 1985 |